Pure Global

Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition - Trial NCT06409585

Access comprehensive clinical trial information for NCT06409585 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Edinburgh and is currently Recruiting. The study focuses on Heart Failure With Preserved Ejection Fraction,Hypertrophic Cardiomyopathy,Cardiac Sarcoidosis,Hypertensive Heart Disease,Tako Tsubo Cardiomyopathy,Arrhythmogenic Right Ventricular Cardiomyopathy 1,Myocarditis. Target enrollment is 290 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06409585
Recruiting
diagnostic test
Trial Details
ClinicalTrials.gov โ€ข NCT06409585
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition

Study Focus

Sponsor & Location

University of Edinburgh

Edinburgh, United Kingdom

Timeline & Enrollment

N/A

May 01, 2023

Jan 01, 2026

290 participants

Primary Outcome

Standardised uptake values,Target-to-background ratio

Summary

Heart scarring, also known as fibrosis, plays a major role in a lot of heart muscle
 abnormalities. These abnormalities of the heart muscle can lead to major issues such as
 symptoms of heart failure, dangerous heart rhythm disturbances and even death. However, a lot
 of these conditions are still not fully understood and treatment options are limited. We here
 aim to use a new radioactive dye called 68Ga-FAPI to identify patterns and the activity of
 heart muscle scarring. This radioactive dye is being used in humans particularly in
 identifying and monitoring cancers and has shown promise in identifying scarring in the heart
 as well. This will help us not only understand the underlying disease process and risk
 stratify these patients but also potentially help us develop new targeted therapies that can
 affect heart muscle scarring. Participants will undergo a baseline MRI scan using this new
 dye and a plain MRI scan will repeated 12-18 months after to see if there are any changes in
 the process.

ICD-10 Classifications

Hypertensive heart disease with (congestive) heart failure
Heart failure
Hypertensive heart disease without (congestive) heart failure
Other ill-defined heart diseases
Heart failure, unspecified

Data Source

ClinicalTrials.gov

NCT06409585

Non-Device Trial